Related Experiment Videos
Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha
A Minami1, K Fujimoto, Y Ozaki
1Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.
Abstract:
Recombinant human interleukin-1 alpha augmented resistance of mice to microbial infections caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, Salmonella typhimurium, and Candida albicans. The effective doses of interleukin-1 alpha ranged from 0.01 to 10 micrograms per mouse, depending on the infecting organism, route of administration, and challenge dose. Intravenous interleukin-1 alpha was, dose for dose, more effective than intravenous muramyl dipeptide and lentinan against the P. aeruginosa and K. pneumoniae infections. Augmentation by interleukin-1 alpha of resistance to infection was also observed in P. aeruginosa-infected mice in a state of cyclophosphamide-induced leucopenia. Interleukin-1 alpha may be useful for controlling obstinate infections not curable by antimicrobial agents alone.
Insights
Recombinant human interleukin-1 alpha enhances mouse resistance to various microbial infections, including bacteria and fungi. This cytokine shows potential for treating difficult infections unresponsive to conventional antimicrobial therapies.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Infections caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, Salmonella typhimurium, and Candida albicans pose significant health challenges.
- The development of novel therapeutic strategies to combat resistant microbial infections is crucial.
Purpose of the Study:
- To investigate the potential of recombinant human interleukin-1 alpha (IL-1α) in augmenting host resistance against a spectrum of microbial pathogens.
- To compare the efficacy of IL-1α with other immunomodulators and assess its effectiveness in immunocompromised models.
Main Methods:
- Mice were treated with varying doses of recombinant human IL-1α via different routes of administration.
- Mice were challenged with specific microbial pathogens (P. aeruginosa, K. pneumoniae, S. aureus, S. pneumoniae, S. typhimurium, C. albicans).
- Efficacy was assessed by survival rates and compared to treatments with muramyl dipeptide and lentinan, and in cyclophosphamide-induced leucopenic mice.
Main Results:
- Recombinant human IL-1α significantly increased survival rates in mice infected with all tested microbial pathogens.
- Effective IL-1α doses ranged from 0.01 to 10 µg/mouse, varying by pathogen and administration route.
- Intravenous IL-1α demonstrated superior efficacy compared to muramyl dipeptide and lentinan against P. aeruginosa and K. pneumoniae.
- IL-1α also enhanced resistance in P. aeruginosa-infected mice with cyclophosphamide-induced leucopenia.
Conclusions:
- Recombinant human IL-1α effectively augments host defense against a broad range of bacterial and fungal infections in mice.
- IL-1α exhibits potent immunomodulatory effects, outperforming other agents in specific infection models.
- Human IL-1α holds promise as an adjunctive therapy for managing severe and drug-resistant microbial infections.